THE "NEW" PROSTATE CANCER INFOLINK

An article in Progrès en urologie states that the prostate cancer-specific mortality rate in France has been dropping by 2.5 percent per year.

Audenet and Rouprêt note that in France — as in America — prostate cancer is the second leading cause of cancer-specific deaths among men.

They argue that:

• The major therapeutic options are still surgery, radiotherapy, and androgen deprivation therapy (ADT) — either alone or in combination.
• The combination of radiation therapy with ADT is the French “gold standard” of therapy (although we suspect others might not agree with that statement).
• The improvements in available diagnostic tools are allowing a more personalized management of prostate cancer patients.
• The development of newer prognostic factors (early PSA assay, time to reach PSA nadir) is contributing to provide better patient diagnosis and monitoring.
• Technical advances in surgery and radiotherapy, along with new methods of androgen suppression, should continue this trend.

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: France, mortality, prostate cancer-specific |